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Abstract
Background: Monoclonal (M) components can interfere 
with the direct bilirubin (D-Bil) assay on the AU Beckman 
Coulter instrumentation and produce spurious results, 
such as D-Bil values greater than total bilirubin (T-Bil) 
or very low/negative D-Bil values. If properly detected, 
this interference may uncover undiagnosed patients with 
monoclonal gammopathy (MG).
Methods: We investigated the interference rate on the 
D-Bil AU assay in serum samples known to contain M pro-
teins along with their isotype and described the protocol 
set up in our laboratory to help with the diagnosis of MG 
based on D-Bil spurious results as first indication.
Results: During a period of 4 years, 15.4% (345 of 2235) of 
serum samples containing M immunoglobulins produced 
erroneous D-Bil results, although no clear relationship 
between the magnitude or isotype of the M component 
and interference could be found. In total 22 new patients 
were diagnosed with MG based on the analytical artefact 
with the D-Bil as first indication.
Conclusions: The D-Bil interference from MG on the 
Beckman AU analysers needs to be made known to labo-
ratories in order to prevent clinical confusion and/or addi-
tional workup to explain the origin of anomalous results. 
Although this information may not add to the manage-
ment of existing patients with serum paraproteins, it can 
benefit patients that have not been diagnosed with MG by 
triggering follow up testing to determine if M components 
are present.
Keywords: direct bilirubin; interference; monoclonal 
component; monoclonal gammopathy; paraprotein.
Introduction
It is well reported in literature that monoclonal (M) com-
ponents (or paraproteins) may interfere with an extensive 
range of analytical techniques [1, 2], routine chemistry 
methods among them [3, 4]. Specifically, the total biliru-
bin (T-Bil) assay with the Roche platforms [5, 6] and the 
direct bilirubin (D-Bil) method with the AU Beckman 
Coulter platforms [6–8] have been shown to occasionally 
produce spurious results in the presence of M proteins 
of high concentration due to abnormal reactions with 
measurement reagents [9]. Efforts to detect such inter-
fered results are not systematically carried out in clinical 
 laboratories, even though this would be interesting for 
 different reasons.
For instance, elevated T-Bil values with low (that is, 
within reference population intervals) D-Bil levels are 
clinically possible as, for example, in haemolytic anaemia 
or liver disease. As a result, interfered samples provid-
ing spuriously high T-Bil results might be incorrectly 
suspected of presenting one of the previously mentioned 
medical conditions (even if the patient is known to have 
a paraprotein), which may trigger unnecessary additional 
diagnostic procedures to investigate the cause of this high 
T-Bil value. This problem could be significantly minimised 
if a warning flag to inform of an anomalous reaction data 
would be implemented by the manufacturers of automatic 
analysers, as recently described for a T-Bil assay [9].
As for D-Bil analyses, M protein interference may 
not even be detected if the T-Bil is normal and, therefore, 
the D-Bil is not quantified. However when both tests are 
analysed simultaneously and the D-Bil level is higher 
than the T-Bil or negative D-Bil values are obtained, some 
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investigation should be carried out to verify if an M protein 
interference is the cause of the spurious results. In 2005, 
Nauti et al. [7] first described examples in three patients 
with IgG kappa paraproteins whose D-Bil values measured 
on the AU analysers (previously Olympus Diagnostics) 
were an order of magnitude greater than the correspond-
ing T-Bil values. Later, Yang et al. [6] demonstrated that 
this method-specific interference could be more frequent 
than suspected as they reported a percentage of interfer-
ence as high as 44% in sera containing M components, 
with approximately 16% of samples with D-Bil values 
greater than the T-Bil and 28% of samples with negative 
D-Bil values. This last possibility is more likely to be over-
looked in everyday work of clinical laboratories. In fact, 
M protein interference may cause not only negative, but 
also low D-Bil values, which might not be flagged by the 
system and pass unnoticed. To detect such interference, 
Yang et al. monitored manually the photometric reaction 
of each measurement as, unfortunately, the AU instru-
ments do not allow raising flags based on the kind of 
anomalous reaction data described to be produced by this 
interference [6]. More recently, Song et al. [8] reported that 
the D-Bil AU assay may be affected not only by monoclo-
nal but also by polyclonal immunoglobulins.
While it is important to know that some assays can be 
interfered by paraproteins and lead to misdiagnosis [10], 
an even more important effect could be drawn from detec-
tion of all M protein interferences in T- or D-Bil results. In 
fact, it is possible from such anomalous results to identify 
undiagnosed patients with MG. This fact has somewhat 
been suggested in the publications cited above but it has 
not been systematically studied. For example, Seimiya 
et  al. [9], after introducing a warning flag in the T-Bil 
reaction data in their BM series JEOL analyser, detected 
seven samples having M proteins (from a total of 30,731 
samples over a period of 2 months). This anomalous reac-
tion was the first indication for conducting electropho-
resis and immunofixation tests in three of these cases. 
Since approximately 3% of people over 50  years of age 
have a MGUS (monoclonal gammopathy of undetermined 
significance) [11] and its progression to malignancy is 
approximately 1% per year [12], one can speculate that the 
number of samples containing paraproteins which can 
interfere in some of the chemistry assays may be greater 
than reported, as the study by Seimiya et al. [9] seems to 
indicate.
Considering all of the above, the aim of this study 
was twofold. The first aim was to investigate, over a large 
period of time (4 years), the patients being seen at the 
Haematology Department of the Hospital Universitario 
Miguel Servet (HUMS) possibly having M proteins, for the 
magnitude of the effect of M proteins on the D-Bil assay 
along with the isotype of the M component. Secondly, 
and considering that at our Centre there were no limita-
tions on clinicians ordering simultaneously T-Bil and 
D-Bil tests, we systematically studied all samples having 
a D-Bil value greater than the T-Bil or, alternatively, those 
with suspiciously low D-Bil values, for the presence of an 
unsuspected MG.
Material and methods
Samples and definition of interference in the D-Bil assay
We reviewed the D-Bil and T-Bil results for 2235 serum samples (from 
June 2010 to May 2014) from 617 different patients studied at the 
Haematology Department of the HUMS suspected of, or under study 
for, having M proteins confirmed by immunofixation, for falsely 
increased (above the T-Bil) or suspiciously low D-Bil concentrations. 
When an initial suspiciously low D-Bil result was obtained, parapro-
tein interference was considered to be demonstrated when repetition 
of analysis produced markedly variable results, as proposed by Yang 
et al. [6]
Alternatively, during the same period of time, 27 serum samples 
collected from patients not suspected to have MG and whose D-Bil 
values were anomalous (greater than the T-Bil or suspiciously low) 
were investigated to determine the presence of a M protein by IgG, IgA 
and IgM quantification, protein electrophoresis and  immunofixation.
In all cases, only samples free of hemolysis, icterus, and lipemia 
(determined by routine photometric measurements) were included 
in the study. As expected over such a long period of time, several 
samples from the same patients were obtained at different times, 
especially in the case of those followed up at the Haematology 
Department, so it was possible to evaluate the relationship, within 
the same patients, between the M protein magnitude and the interfer-
ence. Due to the high subjectivity of the evaluation of the M concen-
tration by densitometry (uncertainty on how to set the limits of the M 
peak and inclusion of the polyclonal background on which it sits), it 
was preferred to use the immunoglobulin concentration correspond-
ing to the M isotype in the study. Also, for the sake of simplicity, the 
small number of samples with free light chains components, heavy 
chains components, or double M components were excluded from 
evaluation.
Written informed consent was obtained from all patients 
 followed up at the Haematology Department and also from the addi-
tional 27 patients further studied to assess the presence of a MG. 
The study was approved by the Hospital Universitario Miguel Servet 
 Ethics Committee.
Instrumentation
D-Bil, T-Bil and total protein (TP) concentrations were measured 
on the AU analysers (Beckman Coulter, Brea, CA, USA). Details of 
the D-Bil AU assay fundamentals along with the cause of interfer-
ence by M proteins can be found elsewhere [6, 8]. IgG, IgA, and IgM 
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concentrations were determined by nephelometry on the Immage 
800 apparatus (Beckman Coulter). Serum protein electrophoresis 
and immunofixation were carried out with the HYDRASYS system 
(Sebia, Norcross, GA, USA). The M protein concentration was calcu-
lated by multiplying the relative density of the M band provided by 
electrophoresis by the TP concentration.
Results
Interference rate in samples known to 
contain an M component
From a total of 2235 samples from 617 different patients 
studied at the Haematology Department and having a 
serum M protein confirmed by immunofixation, 137 (6.1%) 
produced D-Bil results greater than the T-Bil. Suspiciously 
low D-Bil results were obtained for 237 samples, although 
only in 208 cases (that is, 9.3% of the total number of 
samples) interference by an anomalous reaction could be 
demonstrated by obtaining highly variable results after 
analysis repetition (four replicates in two consecutive runs 
of the same sample aliquot). Table 1 shows several exam-
ples of replicate results obtained with those samples. As 
can be seen, very low values maintained an acceptable 
concordance between replicates, whereas in suspicious 
samples an initial very low or even negative value was 
followed by highly variable replicates, some of them well 
above the T-Bil result.
Thus, the total interference rate calculated was 15.4% 
(345 of 2235). If samples with low M concentration were 
excluded from this evaluation (that is, only M components 
whose concentration was  > 20 g/L for IgG, 15 g/L for IgA 
and 10 g/L for IgM were considered) the percentage of 
samples interfered was 32.9%, 283 of 861 samples, 14.1% 
with a D-Bil greater than the T-Bil and 18.8% with spuri-
ously low results, respectively.
With respect to the M concentration and isotype of 
the samples interfered, Table 2 displays the number of 
samples reviewed and the percentage of interference 
calculated for each M isotype. This is shown consider-
ing all the samples with the same isotype as a whole, or 
separated into arbitrary ranges of concentration for each 
isotype (normal-slightly incremented, high and overtly 
high). As seen from this Table, the higher the M concen-
tration, the greater the possibility of interference.
Finally, for samples from the same patients obtained 
at different times and which exhibited interference on 
at least one occasion, this seemed to occur when the M 
concentration tended to be higher, but similar M concen-
trations at other instances did not produce overtly anom-
alous D-Bil results. These details are shown for selected 
patients in Figure 1.
Unsuspected diagnosis of monoclonal 
 gammopathy by D-Bil spurious results
The exact number of D-Bil determinations carried out in 
our laboratory from adult patients not known to contain 
M proteins in the 4 years of study is difficult to evaluate 
with precision, but a figure of 300,000 will not be far 
from reality. After excluding the main causes of interfer-
ence in the T-Bil and D-Bil assays (as intense hemolysis 
or lipemia, for example), a total of 27 samples from adult 
patients without previous results indicating the existence 
Table 1: Examples of the variability obtained for replicate D-Bil analyses of samples that provided an initial suspiciously low D-Bil result.
   Total bilirubin, mg/L   Direct bilirubin, mg/La   Conclusion
Replicate 1  Replicate 2  Replicate 3  Replicate 4  SDb
Sample 1  4.4  –0.3  1.9  –28.5  –5.9  11.3  Interfered
Sample 2  3.1  –0.1  –0.2  0.5  0.1  0.3  True low
Sample 3  4.2  0.3  0.6  0.6  0.7  0.2  True low
Sample 4  5.0  –4.3  0.9  4.9  7.9  5.3  Interfered
Sample 5  6.7  0.1  4.1  –5.0  1.5  3.8  interfered
Sample 6  3.5  –0.6  0.5  0.5  0.3  0.5  true low
Sample 7  5.6  –1.3  –2.6  0.8  1.7  2.0  interfered
Sample 8  4.6  –0.6  6.2  –4.5  8.6  6.0  interfered
aThe limit of detection of the D-Bil AU assay is 0.14 mg/L, so measurements below this value are informed in laboratory reports as  < 0.14. 
Here we have preferred to represent the real value obtained in each replicate to illustrate the variability of each sample whose initial value 
was considered suspicious of being interfered. bSD, Standard deviation of the four replicates. With clearly variable results, samples were 
classified as “interfered” and further assayed for the existence of paraproteins. Samples with fairly homogeneous results were classified 
as “true low”.
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Figure 1: Relationship between M component concentration and interference in the D-Bil AU Beckman Coulter assay in samples from 10 
selected patients with IgG kappa paraproteins collected at different times over a period of 4 years.
Table 2: Interference rate on the D-Bil AU assay with samples from patients followed up at the Haematology Department of the HUMS, 
known to contain paraproteins and with a serum M component confirmed by immunofixation.
Isotype    Number (%) of samples with M component    n (%) of samples interfered
n (% total samples)  Ig concentration, g/L (arbitrary range)  n (% same isotype) % same isotype  % same concentration
IgG kappa   989 (44.3%)   < 20 (normal-slightly high)   565 (57.1%)  169 (17.1%)  29 (5.1%)
    20–40 (high)   358 (36.2%)    100 (27.9%)
     > 40 (overtly high)   66 (6.7%)    40 (60.6%)
IgG lambda   458 (20.5%)   < 20 (normal-slightly high)   319 (70.7%)  77 (16.8%)  21 (6.6%)
    20–40 (high)   126 (27.5%)    46 (36.5%)
     > 40 (overtly high)   13 (2.8%)    10 (76.9%)
IgA kappa   247 (11.1%)   < 15 (normal-slightly high)   152 (61.5%)  17 (6.9%)  2 (1.3%)
    15–30 (high)   63 (25.5%)    8 (12.7%)
     > 30 (overtly high)   32 (13.0%)    7 (21.9%)
IgA lambda   160 (7.2%)   < 15 (normal-slightly high)   99 (61.9%)  33 (20.6%)  6 (6.1%)
    15–30 (high)   46 (28.8%)    15 (32.6%)
     > 30 (overtly high)   15 (9.4%)    12 (80.0%)
IgM kappa   295 (13.2%)   < 10 (normal-slightly high)   193 (65.4%)  47 (15.9%)  3 (1.6%)
    10–20 (high)   49 (16.6%)    12 (24.5%)
     > 20 (overtly high)   53 (18.0%)    32 (60.4%)
IgM lambda  86 (3.8%)   < 10 (normal-slightly high)   46 (53.5%)  2 (2.3%)  1 (2.2%)
    10–20 (high)   22 (25.6%)    1 (4.5%)
     > 20 (overtly high)   18 (20.9%)    0 (0.0%)
Total   2235 (100%)  Normal-slightly high   1374 (61.5%)  345 (15.4%)  62 (4.5%)
    high   664 (29.7%)    182 (27.4%)
    overtly high   197 (8.8%)    101 (51.3%)
They are classified regarding paraprotein isotype and, within each isotype, stratified in arbitrary ranges of normal-slightly high, high and 
overtly high concentration of the corresponding immunoglobulin isotype.
of an M component exhibited anomalous D-Bil results. 
Therefore, the presence of paraproteins was subsequently 
investigated in these 27 cases. In 22 of these patients an 
M component was identified and the patients were trans-
ferred to the Haematology Department where the MG 
was formally diagnosed and classified. Table 3 shows 
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analytical and clinically relevant information from these 
patients. The existence of an M component could not be 
demonstrated for the remaining five samples, but they 
showed elevated polyclonal immunoglobulins, support-
ing the conclusions presented in the work by Song et al. 
[8] that polyclonal immunoglobulins may also interfere 
the D-Bil AU assay.
Interestingly, in those 22 patients newly diagnosed 
with MG because of a D-Bil spurious result as first indica-
tion, most of them (68%, 15 of 22) exhibited an initial D-Bil 
result greater than the T-Bil, and only in seven cases (32%) 
an initial suspiciously low result was obtained.
Discussion
Literature contains numerous examples of unsuspected 
diagnosis of MG arising from spurious results for most 
chemistry tests [4], or even from serum indexes [13], 
but these findings have been often isolated and not 
systematically studied. The protocol that we describe in 
this publication was established in collaboration with 
the Haematology Department of our hospital, and is to be 
used for detecting the analytical interference and utilising 
this information to diagnose patients with MG prior to the 
appearance of symptoms.
As the AU instrumentation does not allow to auto-
matically raise flags based on photometric readings, we 
implemented a protocol where the Laboratory Informa-
tion System (LIS) flagged all suspicious D-Bil results. In 
this sense, D-Bil values above the corresponding T-Bil 
value or below 0.4 mg/L (a value that, in some cases, 
can be considered suspiciously low) were flagged. Those 
flagged results are invalidated by the LIS and must be 
reviewed one by one by laboratory specialists. In the case 
of low D-Bil results, the specialist must decide whether 
repeating the measurement or approving it, based on the 
patient clinical and laboratory history being easily acces-
sible from the LIS. In that way, most D-Bil spurious results 
are confirmed to be from patients already known to have 
paraproteins (or from samples with intense hemolysis or 




  Direct bilirubin, 
mg/L (0.0–2.0)
  Total bilirubin, 
mg/L (3.0–12.0)
  IgA, g/L 
(0.8–3.5)
  IgG, g/L 
(6.5–16.0)
  IgM, g/L 
(0.5–3.0)
  Isotype   M com., 
g/L
  Pathologya
Patient 1   4.3  4.0  3.4  31  0.7  Polyclonal    
Patient 2   14.7  4.2  0.6  12.4  0.4  IgG lambda   9.1  MGUS
Patient 3   4.4  3.2  1.8  17.5  1.5  IgG kappa   12.0  MGUS
Patient 4    < 0.14  3.8  6.0  23  1.8  Polyclonal    
Patient 5   4.7  4.0  0.3  7.3  22  IgM Kappa   13.3  WM
Patient 6   9.1  3.6  1.1  18.7  0.3  IgG Kappa   14.2  MM
Patient 7   50.8  7.9  0.3  30  0.2  IgG Kappa   21  MM
Patient 8   16.2  6.2  0.8  28  0.4  IgG Lambda  21  MM
Patient 9   56.4  4.9  0.3  61  0.1  IgG Lambda  40  MM
Patient 10   4.8  4.1  1.3  28  0.4  IgG Kappa   13.6  MM
Patient 11   4.1  3.8  5.4  33  1.3  Polyclonal    
Patient 12   13.9  8.4  1.4  19.2  0.5  IgG Kappa   8.0  MGUS
Patient 13   11.2  4.3  1.7  3.7  71  IgM Kappa   53  WM
Patient 14    < 0.14  3.1  0.2  33  0.2  IgG Lambda  26  MM
Patient 15    < 0.14  4.5  1.8  22  1.7  IgG Kappa   15.8  MGUS
Patient 16   10.8  3.0  1.4  25  0.6  IgG Kappa   18.0  MGUS
Patient 17   7.0  2.9  25  2.2  0.5  IgA Lambda  30  MM
Patient 18   5.4  4.1  1.2  6.5  20  IgM Kappa   13.1  WM
Patient 19    < 0.14  5.9  35  9.9  0.3  IgA Lambda  22  MM
Patient 20   11.8  3.4  8.5  36  2.8  Polyclonal    
Patient 21    < 0.14  2.8  4.3  42  1.2  Polyclonal    
Patient 22    < 0.14  3.4  0.4  80  0.1  IgG Kappa   59  MM
Patient 23    < 0.14  4.0  0.3  72  0.1  IgG Kappa   48  MM
Patient 24    < 0.14  5.3  79  3.3  0.1  IgA Lambda  49  MM
Patient 25   5.2  5.1  2.9  15.3  0.7  IgG Kappa   12.9  MGUS
Patient 26    < 0.14  3.0  0.1  100  0.1  IgG Kappa   60  MM
Patient 27   27.4  4.4  0.1  53  0.1  IgG Kappa   38  MM
aMGUS, Monoclonal gammopathy of undetermined significance; WM, Waldenström’s macroglobulinemia; MM, myeloma multiple.
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lipemia) and only 2–3 samples on a daily basis (from a 
total of 900 D-Bil determinations per day) are subjected to 
analysis repetition (see Table 1). As all this information is 
freely accessible from the same computer, it only requires 
some minutes of additional work. Finally, the samples not 
known to contain paraproteins and suspected of interfer-
ence are subsequently analyzed in our laboratory to verify 
its presence, by means of immunoglobulin quantification, 
protein electrophoresis and, if appropriate, immunofixa-
tion. When a paraprotein is diagnosed, the Haematology 
Department is notified so they can commence the patient 
clinical evaluation and management. Most patients diag-
nosed with MG in this way (Table 3) were being evaluated 
for other pathological conditions such as pneumonia, 
bone pain disorders and some of them were totally asymp-
tomatic at the time of the diagnosis. Therefore, in these 
cases, the protocol developed has helped to diagnose MG 
at least several months earlier, which represents a clear 
benefit for these patients.
Interestingly, our study also seems to indicate that 
some patients may have been missed by the protocol 
set up in our laboratory or that, unfortunately, it is not 
always correctly applied, since the percentage of samples 
unknown to contain paraproteins with an initial suspi-
ciously low D-Bil value (32%, 7 out of 22) is lower than 
those further studied as a consequence of a D-Bil greater 
than the T-Bil. This is in contradiction with our own results 
obtained with the patients known to have an M protein 
(69% of samples interfered presented an initial low D-Bil 
value) and also with the percentages reported in other 
works (64% and 55% in references 6 and 8, respectively). 
This clearly highlights the weakness of only employing 
the LIS for detecting anomalous results, and reinforces 
the idea that present instrumentation should be supplied 
with an adequate flagging system to monitor all reactions 
carried out. Only in this way, all the samples interfered 
in the D-Bil AU assay would be detected, even those that 
provide completely reasonable results (see, e.g. some of 
the replicates in Table 1).
Conclusions
The interference on the D-Bil AU assay produced by para-
proteins is patient dependent and therefore, specific to 
the particular M protein. In addition, for the majority of 
patients who exhibited interference, this only occurs with 
high M concentrations.
For patients already known to have serum parapro-
teins, this knowledge could only serve to avoid additional 
workup, but for patients not diagnosed with MG it should 
call for additional testing to assess the presence of M 
components.
The discovering of this interference based on the 
initial D-Bil result obtained with each sample is clearly 
unsatisfactory, as even interfered reactions could provide 
a reasonable value by mere chance, so that they will not 
be flagged by the LIS and, therefore, will be skipped from 
revision. We do encourage the manufacturer to include a 
warning of this interference in the D-Bil technical infor-
mation to promote its knowledge to all new users and, 
most importantly, to develop a reaction data monitoring 
system so that all anomalous D-Bil measurements can be 
properly detected.
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